Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

Summary

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Amyotrophic Lateral Sclerosis
• Movement Disorders
• Degenerative Disorder
• Motor Neuron Disease

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Target ALS Foundation, Inc.

Last updated on ClinicalTrials.gov

November 21, 2025

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites